FundingWatcher
Home / Startups / Top health care startups / Health care startups that raised Series C / Health care startups that raised Series C in China

Health care startups that raised Series C in China

Updated 16 Nov 2026

Reset
Health care startups that raised Series C in China
One-time CSV
  • 309 funded companies, 228 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-health-care--series-c~china-500a.csv309 rows × 18 columns
CompanyCityLast roundAmountDate
Nutshell TherapeuticsShanghaiSeries C$40.0M2026-09-15
QL BiopharmaBeijingSeries C$44.7M2026-09-14
Kossel MedicalSuzhouSeries C$59.5M2026-09-01
AusperBioHangzhouSeries C$120.0M2026-08-27
Diyingjia TechnologyBeijingSeries C$3.0M2026-07-28
Delova BiotechQixiaSeries C$88.6M2026-07-22
Weikaier Pharmaceutical TechnologyNanjingSeries C$29.6M2026-06-02
YolTech TherapeuticsMinhangSeries C$73.8M2026-05-29

8 rows of the CSV in 5 of its 18 columns.

309
Startups
$10.2B
Total raised
40
Funded in the last 12 months
$1.3B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 309
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Nutshell Therapeutics Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. Artificial intelligence Shanghai Series C $40.0M 2026-09-15 $75.2M Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 51 to 100 2013
QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
Kossel Medical Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. Health care Suzhou Series C $59.5M 2026-09-01 $103.0M Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 501 to 1,000 2013
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Diyingjia Technology Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. Artificial intelligence Beijing Series C $3.0M 2026-07-28 $32.3M IDG Capital, Legend Capital, Microsoft Accelerator 11 to 50 2017
Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
Ruining Bio Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection and wound repair. Health care Jiading Series C $14.6M 2026-02-28 $38.8M Qiming Venture Partners, Taiyu Investment, Dingxin Capital +1 2018
Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
Darwin Cell Biology Darwin Cell Biology provides cell biotechnology services. Biotech Beijing Series C $27.9M 2025-12-08 $62.4M Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment 11 to 50 2016
Healsun Biopharm Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. Biotech Hangzhou Series C $27.8M 2025-11-19 $101.3M Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 251 to 500 2015
GRIT Biotechnology GRIT Biotechnology develops tumor infiltrating lymphocyte immunotherapy for solid tumors. Biotech Shanghai Series C $84.0M 2025-10-14 $153.5M Matrix Partners China, Hillhouse Investment, CICC +2 51 to 100 2019
Yantai Lannacheng Biotechnology Yantai Lannacheng Biotechnology develops Class I diagnostic medications. Biotech Yantai Series C $41.8M 2025-07-20 $103.8M Shenzhen Capital Group, Qianhai Fund of Funds, Yuanhe Capital +1 1 to 10 2021
Tianchen Biotechnology Tianchen Biotechnology develops and sells medical products for ophthalmology. Biotech Tianjin Series C $27.8M 2025-06-03 $41.7M CMB International Capital Corporation 2018
LongBio Pharma LongBio Pharma develops treatments for patients with complement and allergy diseases. Biotech Pudong Series C $28.9M 2025-05-27 $51.1M Oriental Fortune Capital, Shanxi Securities Investment, Hefei Hongda +2 11 to 50 2020
Neusoft Zhirui Neusoft Zhirui provides precision tumor radiation technology, products, and solutions. Health care Shenyang Series C $13.8M 2024-06-17 $13.8M Leli Capital 51 to 100 2018
Cipher Gene Tech Cipher Gene Tech operates a biomedical big data analysis and interpretation platform. Health care Beijing Series C $13.8M 2024-05-27 Everest Venture Capital, Shenzhen Guozhong Venture Capital Management, Microsoft Accelerator +1 11 to 50 2015
Zhiyi Pharmaceutics Zhiyi Pharmaceutics researches and develops second-generation probiotics and live biotherapeutics. Biotech Guangzhou Series C $13.8M 2024-03-28 Shenzhen Capital Group, SDIC Venture Capital, Sinoking Capital 51 to 100 2013
Hengruiyuan Hengruiyuan develops immune cell-based medications for treating solid tumors. Biotech Songjiang Series C $14.1M 2024-01-09 $42.8M Haiyuan Capital, Zhongke Kechuang 501 to 1,000 2015
DIAGENS DIAGENS is a Hangzhou-based biotechnology firm that provides in-vitro diagnostic products and medical equipment. Biotech Hangzhou Series C $14.1M 2023-12-29 Shenzhen Guozhong Venture Capital Management, Haiyuan Capital, China Venture Capital HRVC +2 51 to 100 2014
Qitan Technology Qitan Technology develops genome sequencing technology. Biotech Chengdu Series C $14.1M 2023-12-28 Hillhouse Investment, Gaorong Capital, CDH Investments +1 51 to 100 2016
Langhe Medical Langhe Medical focuses on early lung cancer diagnosis and non-invasive interventional treatment. Hardware Xuhui Series C $13.9M 2023-12-12 $13.9M TaiKun Fund 2015
Zenshine Pharma Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. Biotech Nanjing Series C $13.7M 2023-10-13 $28.7M Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 11 to 50 2018
SPH Health Commerce SPH Health Commerce operates an Internet hospital and online pharmacy. Commerce Xuhui Series C $68.5M 2023-10-12 New Alliance Capital, Shanghai Biomedical Industrial Equity Investment Fund, China Reform Holdings Corporation 501 to 1,000 2015
LYNK Pharmaceuticals LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. Biotech Hangzhou Series C $16.7M 2023-09-21 Legend Capital, Kaitai Capital, New Alliance Capital +2 11 to 50 2018
Konfoong Biotech International Konfoong Biotech International is a biotechnology company. Artificial intelligence Ningbo Series C $14.9M 2022-07-12 Intel Capital, Yinxinggu Capital 101 to 250 2011
Edge Medical Robotics Edge Medical Robotics designs, develops, and commercializes surgical robot platforms and medical devices. Hardware Shenzhen Series C $200.0M 2021-11-05 $308.0M Temasek, Mirae Asset Venture Investment, OrbiMed +1 11 to 50 2017
Kindo Kindo provides medical insurance and medical data services. Fintech Wuhan Series C $4.8M 2018-02-06 $12.2M Fortune Venture Capital, Breakthrough Capital 51 to 100 2013
Brightease Brightease provides mental health services, software, and hardware products. Health care Fengtai Series C $4.4M 2010-09-09 Legend Holdings, Changrun Capital 251 to 500 2007

Table 1. Health care startups that raised Series C in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 309.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
2 Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
3 Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
4 YolTech Therapeutics YolTech Therapeutics combines LNP delivery with gene editing technology for biotechnology applications. Biotech Minhang Series C $73.8M 2026-05-29 $144.9M K2VC, UnityVC, Decheng Capital +1 11 to 50 2021
5 Kossel Medical Kossel Medical develops and manufactures vascular interventional devices and clinical system solutions. Health care Suzhou Series C $59.5M 2026-09-01 $103.0M Fortune Venture Capital, Suzhou International Development Venture Capital, Ming Bioventures +1 501 to 1,000 2013
6 QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
7 Nutshell Therapeutics Nutshell Therapeutics discovers small-molecule drugs using insights from protein dynamics. Artificial intelligence Shanghai Series C $40.0M 2026-09-15 $75.2M Matrix Partners China, Source Code Capital, Northern Light Venture Capital +1 51 to 100 2013
8 Weikaier Pharmaceutical Technology Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. Biotech Nanjing Series C $29.6M 2026-06-02 $120.4M SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 501 to 1,000 2010
9 Darwin Cell Biology Darwin Cell Biology provides cell biotechnology services. Biotech Beijing Series C $27.9M 2025-12-08 $62.4M Shijingshan Modern Innovation Industry Fund, Shanghai Yungu Investment 11 to 50 2016
10 Healsun Biopharm Healsun Biopharm provides antibody and recombinant protein CRO and CDMO services. Biotech Hangzhou Series C $27.8M 2025-11-19 $101.3M Yinxinggu Capital, Haitong Capital, Dongfang Jiafu +2 251 to 500 2015

Table 2. Health care startups that raised Series C in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Shenzhen Capital Group Venture capital firm Nanshan, China 5 2%
2 Matrix Partners China Venture capital firm Beijing, China 4 1% 1 Nutshell Therapeutics
3 Qiming Venture Partners Venture capital firm Shanghai, China 4 1% 2 AusperBio, Ruining Bio
4 Legend Capital Venture capital firm Beijing, China 4 1% 2 Diyingjia Technology, Delova Biotech
5 Shanghai Biomedical Industrial Equity Investment Fund Venture capital firm Huangpu, China 4 1% 1 Healsun Biopharm
6 Hillhouse Investment Angel group Singapore 4 1%
7 Shenzhen Guozhong Venture Capital Management Venture capital firm Shenzhen, China 4 1%
8 Baidu Ventures Venture capital firm Beijing, China 3 1% 1 Nutshell Therapeutics
9 Northern Light Venture Capital Venture capital firm Beijing, China 3 1% 1 Nutshell Therapeutics
10 Fortune Venture Capital Venture capital firm Shenzhen, China 3 1% 1 Kossel Medical
11 IDG Capital Private equity firm Beijing, China 3 1% 1 Diyingjia Technology
12 SDIC Venture Capital Venture capital firm Xicheng, China 3 1% 1 Weikaier Pharmaceutical Technology
13 Decheng Capital Venture capital firm Menlo Park, United States 3 1% 1 YolTech Therapeutics
14 Sherpa Healthcare Partners Venture capital firm Beijing, China 3 1%
15 Qianhai Fund of Funds Private equity firm Shanzhen, China 3 1%

Table 3. Health care startups that raised Series C in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 142 46% $6.5B
Software 24 8% $597.5M
Hardware 15 5% $483.1M
Artificial intelligence 9 3% $181.6M
Commerce 8 3% $28.0M
Education 2 1% $49.1M
Fintech 2 1% $12.2M
Energy 1 0% $30.0M

Table 4. Health care startups that raised Series C in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 309 100% $21.8M

Table 5. Health care startups that raised Series C in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 50 16%
Beijing 43 14%
Hangzhou 33 11%
Shenzhen 25 8%
Suzhou 23 7%
Nanjing 18 6%
Guangzhou 17 6%
Haidian 12 4%
Wuhan 7 2%
Minhang 6 2%
Changping 5 2%
Tianjin 4 1%

Table 6. Health care startups that raised Series C in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
October 2026 1 2% $30.0M
September 2026 4 10% $184.2M
August 2026 3 8% $157.1M
July 2026 5 12% $188.8M
June 2026 3 8% $73.8M
May 2026 4 10% $168.0M
April 2026 3 8% $123.5M
March 2026 5 12% $49.8M
February 2026 4 10% $102.6M
January 2026 2 5% $86.0M
December 2025 5 12% $58.5M
November 2025 1 2% $27.8M

Table 7. Health care startups that raised Series C in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 34 11% $1.2B
2025 35 11% $798.2M
2024 28 9% $308.6M
2023 31 10% $423.2M
2022 27 9% $465.4M
2021 54 17% $2.9B

Table 8. Health care startups that raised Series C in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2020 to 2022 10 3%
2015 to 2019 132 43%
2010 to 2014 109 36%
Before 2010 55 18%

Table 9. Health care startups that raised Series C in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 26 9%
11 to 50 57 20%
51 to 100 59 20%
101 to 250 70 24%
251 to 500 37 13%
501 to 1,000 24 8%
1,001 to 5,000 15 5%
5,001 to 10,000 1 0%
10,001 or more 1 0%

Table 10. Health care startups that raised Series C in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many health care startups in China whose last round is Series C are on the list?
309, in the file dated 16 November 2026. 40 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 309 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Health care startups that raised Series C in China: 309 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Health care at other stages in China

Other sectors that raised Series C in China

Cite: FundingWatcher, 309 health care companies in China whose most recent round is Series C, 16 November 2026. https://fundingwatcher.com/startups/health-care/series-c/china-500a/